Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 Post published:February 27, 2023 Post category:Press Release
Bright Minds Biosciences Announces Non-Executive Director Appointment Post published:February 17, 2023 Post category:Press Release
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements Post published:February 8, 2023 Post category:Press Release
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Post published:January 28, 2023 Post category:Press Release
Bright Minds Biosciences Announces Resignation of Board Member Post published:January 12, 2023 Post category:Press Release
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement Post published:December 2, 2022 Post category:Press Release
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors Post published:September 8, 2022 Post category:Press Release
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Comments on Recent Trading Activity Post published:August 18, 2022 Post category:Press Release